Abstract 2884: Optimized CD28 bispecific antibodies for targeted activation of T cells within the tumor microenvironment

作者
Sara Majocchi,Pauline Lloveras,Coline Burnet-Merlin,Lise Nouveau,Nicolas Plèche,Pauline Malinge,Claudia Batista,Christelle Daviet,Maud Charreton,Guillemette Pontini,Franck Gueneau,Valéry Moine,Giovanni Magistrelli,Limin Shang,Walter G. Ferlin,Krzysztof Masternak
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:82 (12_Supplement): 2884-2884
标识
DOI:10.1158/1538-7445.am2022-2884
摘要

Abstract Tumor-targeted CD28 bispecific antibodies (bsAbs) are designed to co-stimulate T cells specifically within the tumor microenvironment. By bridging T cells to malignant cells expressing a selected tumor-associated antigen (TAA), CD28 bsAbs deliver the so-called signal 2 to T cells unleashing their full cytotoxic potential. Contrary to bivalent CD28 monoclonal antibody (mAb) superagonists, the activation of CD28 with monovalent CD28 bispecifics requires the binding of a TAA expressed by the cancer cells to induce CD28 clustering. Preclinical studies have shown the benefit of adding costimulatory CD28 bsAbs for the treatment of solid tumors, boosting the efficacy of bispecific T cell engagers (CD3 bsAbs) or PD-(L)1 checkpoint inhibitors. Using our proprietary fully human κλ body antibody platform, which relies on a common heavy chain and on two distinct light chains driving specificity and affinity (i.e., one kappa and one lambda), we have identified a panel of agonist anti-CD28 kappa arms. Using our existing lambda anti-TAA arms (e.g., targeting CD19, MSLN, HER2, EGFR), an array of TAA-CD28 κλ bodies targeting different tumors were generated. The capacity of these CD28 κλ bodies to provide signal 2 to T cells was assessed both in vitro and in vivo in combination with CD3 bsAbs. In the presence of cancer cells and corresponding TAA-CD3 bsAbs, the CD28 κλ bodies enabled the activation of primary human CD4 and CD8 T cells, leading to T cell proliferation and secretion of cytokines such as IL-2 and IFNγ, and granzyme B. Importantly, when used alone or in combination with an untargeted CD3 bsAb (that is, in the absence of signal 1), CD28 κλ bodies showed no sign of T cell activation, potentially limiting peripheral toxicity. The resulting change in the T cell activation status led to a potent in vitro T cell-dependent cellular cytotoxicity (TDCC) against TAA-expressing cancer cell lines. CD28 κλ bodies targeting gastrointestinal tumors were tested in combination with CD3 bsAbs in xenogeneic tumor models and synergistically improved the antitumoral activity of T cell engagers, leading to an enhanced tumor control. Thus, via the identification of optimal agonist anti CD28 arms, CD28 bsAbs targeting multiple TAAs were designed for tumor-specific activation of the immune system. The resulting TAA-CD28 κλ bodies can enhance the antitumor response induced by CD3-retargeting bsAbs via the induction of T cell proliferation and activation, increased cytokine secretion and boosted anti-tumoral cytotoxicity. Other anti-TAA arms are being explored, to expand the panel of TAAs that could be easily paired with our anti-CD28 platform arms. Citation Format: Sara Majocchi, Pauline Lloveras, Coline Burnet-Merlin, Lise Nouveau, Nicolas Pleche, Pauline Malinge, Claudia Batista, Christelle Daviet, Maud Charreton, Guillemette Pontini, Franck Gueneau, Valery Moine, Giovanni Magistrelli, Limin Shang, Walter Ferlin, Krzysztof Masternak. Optimized CD28 bispecific antibodies for targeted activation of T cells within the tumor microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2884.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
爆米花的应助被科研通管家采纳,获得10
1秒前
1秒前
1秒前
Tuniverse_发布了新的文献求助10
1秒前
Ava的应助被科研通管家采纳,获得10
1秒前
嘻嘻哈哈的应助被akl采纳,获得10
1秒前
JamesPei的应助被科研通管家采纳,获得10
2秒前
zmm1发布了新的文献求助10
2秒前
wanci的应助被科研通管家采纳,获得10
2秒前
2秒前
脑洞疼的应助被科研通管家采纳,获得10
2秒前
爆米花的应助被科研通管家采纳,获得10
2秒前
FashionBoy的应助被科研通管家采纳,获得10
2秒前
深情安青的应助被科研通管家采纳,获得10
2秒前
香蕉觅云的应助被科研通管家采纳,获得10
2秒前
搜集达人的应助被科研通管家采纳,获得10
2秒前
丰富的草莓完成签到,获得积分10
3秒前
我是谁的应助被科研通管家采纳,获得30
3秒前
小蘑菇的应助被科研通管家采纳,获得10
3秒前
Owen的应助被科研通管家采纳,获得10
3秒前
Ava的应助被科研通管家采纳,获得10
3秒前
852的应助被潇洒的诗桃采纳,获得10
4秒前
ndj完成签到,获得积分10
4秒前
4秒前
晓槐完成签到,获得积分10
5秒前
小小人儿发布了新的文献求助10
5秒前
随意发布了新的文献求助30
6秒前
WSX发布了新的文献求助10
6秒前
Linanana完成签到,获得积分10
6秒前
2pai完成签到,获得积分10
6秒前
7秒前
7秒前
zk812926完成签到,获得积分20
7秒前
8秒前
8秒前
无花果的应助被zmm1采纳,获得10
9秒前
9秒前
清风若青衣完成签到,获得积分10
10秒前
dahuihui完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182014
求助须知:如何正确求助?哪些是违规求助? 9571728
关于积分的说明 21819478
捐赠科研通 7778441
什么是DOI,文献DOI怎么找? 3433580
关于科研通互助平台的介绍 2557781
邀请新用户注册赠送积分活动 2479640